nAMD

Ophthalmology·MeSH: Retinal Degeneration

Prevalence

81.8 / 100K

10 drugs in development·6 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(9)

Drug	Company
150 ivt	4D Molecular Therapeutics, Inc. (FDMT)
4D-150 IVT	Merus N.V. (MRUS)
eylea	4D Molecular Therapeutics, Inc. (FDMT)
eylea	4D Molecular Therapeutics, Inc. (FDMT)
ixo-vec	Adverum Biotechnologies, Inc. (ADVM)
Ixo-vec (formerly ADVM-022)	Adverum Biotechnologies, Inc. (ADVM)
ixoberogene soroparvovec (Ixo-vec; formerly ADVM-022)	Adverum Biotechnologies, Inc. (ADVM)
lx102	SAB BIOTHERAPEUTICS, INC. (SABS)
OTX-TKI	OCULAR THERAPEUTIX, INC (OCUL)

Phase 2(1)

Drug	Company
th103	Kalaris Therapeutics, Inc. (KLRS)

BioSniper tracks 10 drugs in development for nAMD across 6 companies.

There are 3 clinical trials targeting nAMD tracked by BioSniper.

The estimated prevalence of nAMD is approximately 81.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.